CA2946900A1 - O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine - Google Patents

O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine Download PDF

Info

Publication number
CA2946900A1
CA2946900A1 CA2946900A CA2946900A CA2946900A1 CA 2946900 A1 CA2946900 A1 CA 2946900A1 CA 2946900 A CA2946900 A CA 2946900A CA 2946900 A CA2946900 A CA 2946900A CA 2946900 A1 CA2946900 A1 CA 2946900A1
Authority
CA
Canada
Prior art keywords
hpga
oac
pharmaceutically acceptable
acceptable salt
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2946900A
Other languages
English (en)
French (fr)
Inventor
Yawei Ni
Michael Springer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ology Bioservices Inc
Original Assignee
Nanotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotherapeutics Inc filed Critical Nanotherapeutics Inc
Publication of CA2946900A1 publication Critical patent/CA2946900A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA2946900A 2014-05-08 2015-05-08 O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine Abandoned CA2946900A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990493P 2014-05-08 2014-05-08
US61/990,493 2014-05-08
PCT/US2015/029979 WO2015172077A1 (en) 2014-05-08 2015-05-08 O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine

Publications (1)

Publication Number Publication Date
CA2946900A1 true CA2946900A1 (en) 2015-11-12

Family

ID=53190060

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2946900A Abandoned CA2946900A1 (en) 2014-05-08 2015-05-08 O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine

Country Status (6)

Country Link
EP (1) EP3140324A1 (ja)
JP (1) JP2017514961A (ja)
CN (1) CN106459225A (ja)
AU (1) AU2015255693A1 (ja)
CA (1) CA2946900A1 (ja)
WO (1) WO2015172077A1 (ja)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins

Also Published As

Publication number Publication date
AU2015255693A1 (en) 2016-11-03
EP3140324A1 (en) 2017-03-15
JP2017514961A (ja) 2017-06-08
WO2015172077A8 (en) 2016-01-28
WO2015172077A1 (en) 2015-11-12
CN106459225A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
EP2056871B1 (en) Protein matrix vaccines and methods of making and administering such vaccines
Gupta et al. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin
CA2836251C (en) Protein matrix vaccine compositions including polycations
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
AU2004251734B2 (en) Vaccines against group Y neisseria meningitidis and meningococcal combinations thereof
RU2563354C2 (ru) Адъювант на основе низкомолекулярного пептидогликана клеточной стенки бактерий
Ni et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever
AU2018290298B2 (en) Immunogenic compositions
CA2946900A1 (en) O-acetylated high molecular weight polygalacturonic acids and their use as vi polysaccharide vaccine
WO2004003215A1 (en) Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides
Chhibber et al. Immunoprotective potential of polysaccharide-tetanus toxoid conjugate in Klebsiella pneumoniae induced lobar pneumonia in rats
KR20140030233A (ko) 시겔라 소네이 박테리아의 세포외 다당류, 이를 제조하는 방법, 이를 함유한 백신 및 약제 조성물
Korcová et al. Immunomodulative properties of conjugates composed of detoxified lipopolysaccharide and capsular polysaccharide of Vibrio cholerae O135 bound to BSA-protein carrier
안소정 Development of efficient Vi polysaccharide conjugate vaccine and its vaccination strategy for prevention of typhoid fever

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20200831